Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions

Journal of Pharmaceutical and Biomedical Analysis

Volumn 61, Issue , 2012, Pages 277-283

  Ueyama, Eiji ^a   Takahashi, Fumie ^a   Ohashi, Jyunji ^a   Konse, Tomonori ^a   Kishi, Naoyuki ^a   Kano, Kenji ^b  

^a Analytical and Quality Evaluation Research Laboratories   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

AIBN; Degradation product; Heavy oxygen water; Oxidation; Stability

Indexed keywords

1,4 DIHYDROPYRIDINE; 2,2' AZOBISISOBUTYRONITRILE; AZELNIDIPINE; BUTYRONITRILE; DIHYDROPYRIDINE; HYDROGEN; OXYGEN; UNCLASSIFIED DRUG; WATER;

AROMATIZATION; ARTICLE; DEGRADATION; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OXIDATION; PRIORITY JOURNAL; WATER CONTENT;

AZETIDINECARBOXYLIC ACID; CHEMISTRY, PHARMACEUTICAL; DIHYDROPYRIDINES; FREE RADICALS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHARMACEUTICAL SOLUTIONS;

EID: 84856087605     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.12.001     Document Type: Article

References (13)

1. Kuramoto K., Ichikawa S., Hirai A., Kanada S., Nakachi T., Ogihara T., Azelnidipine amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens. Res. 2003, 26:201-208.
2. Nakano K., Egashira K., Tada H., Kohjimoto Y., Hirouchi Y., Kitajima S., Endo Y., Li X.H., Sunagawa K. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. J. Hypertens. 2006, 24:1881-1889.
3. Toyo-Oka T., Nayler W.G. Third generation calcium entry blockers. Blood Press. 1996, 5:206-208.
4. Boccardi G., Deleuze C., Gachon M., Palmisano G., Vergnaud J.P. Autoxidation of tetrazepam in tablets: prediction of degradation impurities from the oxidative behavior in solution. J. Pharm. Sci. 1992, 81:183-185.
5. Boccardi G. Autoxidation of drugs: prediction of degradation impurities from results of reaction with radical chain initiators. Farmaco 1994, 49:431-435.
6. Waterman K.C., Adami R.C., Alsante K.M., Hong J., Landis M.S., Lombardo F., Roberts C.J. Stabilization of Pharmaceuticals to oxidative degradation. Pharm. Dev. Technol. 2002, 7:1-32.
7. Hovorka S.W., Schoneich C. Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J. Pharm. Sci. 2001, 90:253-269.
8. Alsante K.M., Ando A., Brown R., Ensing J., Hatajik T.D., Kong W., Tsuda Y. The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv. Drug Deliv. Rev. 2007, 59:29-37.
9. Alsante K.M., Martin L., Baertschi S.W. A stress testing benchmarking study. Pharm. Technol. 2003, 27:60-72.
10. Nelson E.D., Harmon P.A., Szymanik R.C., Teresk M.G., Li L., Seburg R.A., Reed R.A. Evaluation of solution oxygenation requirements for azonitrile-based oxidative forced degradation studies of pharmaceutical compounds. J. Pharm. Sci. 2006, 95:1527-1539.
11. Nelson E.D., Thompson G.M., Yao Y., Flanagan H.M., Harmon P.A. Solvent effects on the AIBN forced degradation of cumene: implications for forced degradation practices. J. Pharm. Sci. 2009, 98:959-969.
12. Betigeri S., Thakur A., Raghavan K. Use of 2,2(-azobis(2-amidinopropane) dihydrochloride as a reagent tool for evaluation of oxidative stability of drugs. Pharm. Res. 2005, 22:310-317.
13. Eisner U., Sadeghi M.M., Hambright W.P. Free radical oxidation of dihydropyridines. Tetrahedron Lett. 1978, 3:303-306.